Latest news on Covid boosters safety signal; AstraZeneca leads trio of M&A; The biggest news out of #JPM23; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
Hello — we know it’s not Saturday but Monday, but since Endpoints News is taking a break for MLK Day, we thought we’d change up the time this week. Whether you’re recovering from the JP Morgan conference like me or watched from afar, this edition of the Endpoints Weekly has got you covered on everything you need to know from last week. I was thrilled to meet some of you in San Francisco and learned so much from conversations, formal or informal. It’s been more than three years since I’ve stepped foot in the US (or left Asia!), so the trip was extra special.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.